Delivery Order SPE2DB20D2104-SPE2DB24FS27W
- Not listed
- This federal contract award is for the supply of BOTOX 100 UNIT VIALS, with a ceiling value of $10,336.32. The contract was awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) valued at $999,999,999, which serves as a primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and medical...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, to provide Botox 200 unit vials. The $20,956.68 firm-fixed price delivery order is part of a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 between Amerisourcebergen and DLA Troop Support Medical, which serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies...
- This federal contract award is for the delivery of BOTOX 200 UNIT VIALS, awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a ceiling value of $8,547.90 and is a Firm Fixed Price Delivery Order. It does not have a set-aside designation, indicating open competition. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
- This federal contract award is for the procurement of BOTOX 200 unit vials by the Defense Logistics Agency (DLA), a defense agency under the Department of Defense (DoD). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distribution company, through its Corporate Office Division. The contract is a Delivery Order with a Firm Fixed Price pricing type, valued at $6,985.56. The award has an ultimate completion date of June 12, 2024. Amerisourcebergen holds a larger...
- This federal contract award is for the delivery of BOTOX 200 UNIT VIALS to the Defense Logistics Agency (DLA), a defense agency within the U.S. Department of Defense. The $58,213.00 firm fixed-price contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on June 28, 2024. The contract has an ultimate completion date of July 22, 2024 and is not set aside for any specific business designation. Amerisourcebergen holds several large indefinite delivery contracts...
- This federal contract award is for the delivery of 200-unit vials of Botox to the Defense Logistics Agency (DLA), a defense agency within the U.S. Department of Defense. The contract, valued at $11,642.60, was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distribution company. The contract is a Delivery Order with a Firm Fixed Price pricing type and an ultimate completion date of August 5, 2024. The contract does not have a set-aside designation. Amerisourcebergen Drug Corp...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is for the delivery of BOTOX 100 unit vials. The $4,306.80 firm fixed-price contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and has a completion date of February 20, 2025. The contract is not set aside for any particular business type. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
- This federal contract award is for the delivery of BOTOX 200 UNIT VIALS to the Defense Logistics Agency (DLA), a defense agency within the U.S. Department of Defense. The contract was awarded to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a major pharmaceutical distribution company. The contract is a Firm Fixed Price Delivery Order with a ceiling value of $13,971.12 and a completion date of May 23, 2024. The place of performance is Conshohocken, PA. This...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $11,642.60, is for the delivery of 200 unit vials of the medication Botox. It is a firm fixed-price Delivery Order under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen, valued at $999,999,999, to provide a comprehensive range of pharmaceutical products and medical supplies to...
- This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the supply of 200 unit vials of BOTOX to the Defense Logistics Agency (DLA), a component of the U.S. Department of Defense. The award has a ceiling value of $13,971.12 and is structured as a firm-fixed-price delivery order, without any set-aside designation. Amerisourcebergen holds a single-award Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued up to $999,999,999.00 through...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB24FS27WDelivery Order
This federal contract award is for the delivery of Botox 200 unit vials to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a ceiling value of $17,463.90 and is a firm fixed-price delivery order. The contract is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Amerisourcebergen Drug Corp holds with the DLA Troop Support Medical, which serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. The contract has no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which also holds a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs. These IDCs demonstrate Amerisourcebergen's capacity to meet the diverse and critical pharmaceutical needs of multiple government agencies on a large scale.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $17.5k | 1/29/24 |